Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Regulatory and Ethical Aspects of Orthobiologic Therapies

Iain R Murray et al. Orthop J Sports Med. .

Abstract

Orthobiologic therapies show significant promise to improve outcomes for patients with musculoskeletal pathology. There are considerable research efforts to develop strategies that seek to modulate the biological environment to promote tissue regeneration and healing and/or provide symptomatic relief. However, the regulatory pathways overseeing the clinical translation of these therapies are complex, with considerable worldwide variation. The introduction of novel biologic treatments into clinical practice raises several ethical dilemmas. In this review, we describe the process for seeking approval for biologic therapies in the United States, Europe, and Japan. We highlight a number of ethical issues raised by the clinical translation of these treatments, including the design of clinical trials, monitoring outcomes, biobanking, "off-label" use, engagement with the public, marketing of unproven therapies, and scientific integrity.

Keywords: biologics; orthobiologics; oversight; regeneration; regulation.

PubMed Disclaimer

Conflict of interest statement

One or more of the authors has declared the following potential conflict of interest or source of funding: This work was supported by the Orthoregeneration Network. J.C. has received education payments from Arthrex and Smith & Nephew; consulting fees from DePuy, Linvatec, and Smith & Nephew; speaking fees from Linvatec; and hospitality payments from Medical Device Business Services, Medwest, and Stryker. N.S.P. has received research support from Zimmer Biomet Holdings and RegenLab. R.M.F. has received grant support from Arthrex, education payments from Arthrex and Smith & Nephew, nonconsulting fees from Arthrex, and hospitality payments from Joint Restoration Foundation. J.H. has received education payments from Gemini Mountain. B.M. has received speaking fees from Arthrex and consulting fees from Arthrex, Biomarin Pharmaceutical, DePuy, and Exactech. J.L.D. has received grant support from Terumo BCT; consulting fees from Arthrex, Bioventus, DePuy, RTI Surgical, and Zimmer; and nonconsulting fees from Arthrex. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.

References

    1. American Academy of Orthopaedic Surgeons. Standards of Professionalism: Advertising by Orthopaedic Surgeons. Accessed April 4, 2020. https://www.aaos.org/AAOSNow/2007/Jun/youraaos/youraaos5/?Ssopc=1
    1. Barlas S. The 21st Century Cures Act: FDA implementation one year later. Some action, some results, some questions. Pharmacol. Ther. 2018;43(3):149–179. - PMC - PubMed
    1. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 5th ed. Oxford University Press; 2001.
    1. Beitzel K, Allen D, Apostolakos J, et al. US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine. J Knee Surg. 2015;28(1):29–34. - PubMed
    1. Belsky K, Smiell J. Navigating the regulatory pathways and requirements for tissue-engineered products in the treatment of burns in the United States. J Burn Care Res. 2021;42(4):774–784. - PMC - PubMed

LinkOut - more resources